Company intelligence / Profile preview

Eurus Therapeutics

Fujisawa, Kanagawa Prefecture, Japankyoto-unicap.co.jp ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing a proprietary gene therapy and genome editing platform that avoids CRISPR/Cas limitations. The company is currently focused on improving its technology and completing preclinical demonstration experiments aimed at treating genetic diseases. No clinical results reported yet.

Therapeutic areas: Rare Diseases
Modalities: Gene therapyGenome editing (non–CRISPR/Cas system)
Industry: Biotech

Partnerships

Kyoto University Innovation Capital Corporation ("Kyoto iCAP")

Beyond the preview

Go deeper on Eurus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eurus Therapeutics.

Explore the full profile